Home > Boards > Canadian > Cannabis > ABcann Medicinals Inc (TSXV:ABCN)

At ABCN, Medicinal Cannabinoid Quality and Safety are

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
NetworkNewsWire Member Profile
Member Level 
Followed By 35
Posts 3,763
Boards Moderated 35
Alias Born 10/18/16
160x600 placeholder
L'OCRCVM permet la reprise de la négociation - ABCN PR Newswire (Canada) - 2/5/2018 10:12:00 AM
IIROC Trading Resumption - ABCN PR Newswire (Canada) - 2/5/2018 10:11:00 AM
Suspension de la négociation par l'OCRCVM - ABCN PR Newswire (Canada) - 2/5/2018 10:07:00 AM
IIROC Trading Halt - ABCN PR Newswire (Canada) - 2/5/2018 10:06:00 AM
ABcann Global Corporation Announces $70 Million Bought Deal Financing PR Newswire (Canada) - 1/29/2018 7:47:00 AM
Cultivating the Cannabis Lifestyle: Canadian Cannabis Players Gear Up for Recreational Marijuana Legalization NetworkNewsWire - 12/12/2017 8:45:00 AM
Outsized Demand in Canada’s Cannabis Market Triggers Upswing in Smart Money Flowing North NetworkNewsWire - 11/21/2017 7:45:00 AM
Coming Cannabis Recreational Demand in Canada Triggers Massive Investment NetworkNewsWire - 11/20/2017 8:45:00 AM
Rising Demand for Cannabis Oils Pushes Canada’s Producers into Overdrive NetworkNewsWire - 11/15/2017 8:45:00 AM
Canadian Licensed Producers Prepare for Recreational Cannabis Legalization, Expect Significant Growth in Demand NetworkNewsWire - 11/14/2017 8:45:00 AM
The Generational Growth Opportunity for Canadian Cannabis NetworkNewsWire - 10/4/2017 8:45:00 AM
Demand Outpacing Supply as Canadian Cannabis Legalization Looms NetworkNewsWire - 10/3/2017 8:45:00 AM
Production Bottleneck Spells Opportunity for Canada’s Cannabis Producers NetworkNewsWire - 9/21/2017 8:45:00 AM
What it Takes to Thrive in Canada’s Multi-Billion-Dollar Marijuana Industry NetworkNewsWire - 9/19/2017 8:45:00 AM
Cannabis Industry Leaders Drive Growth with Acquisition Strategies and Territorial Expansion NetworkNewsWire - 9/6/2017 8:45:00 AM
MJAC 2017 Speaker Update - How venture capital and cryptocurrency are converging as the future of cannabis investing InvestorsHub NewsWire - 8/30/2017 10:29:33 PM
PotNetwork Holdings, Inc Confirmed for MJAC 2017 InvestorsHub NewsWire - 8/28/2017 10:43:55 AM
MJAC 2017 International Cannabis Conference - Discount Code InvestorsHub NewsWire - 8/24/2017 8:40:00 AM
ABcann Global Corporation Opens the Market PR Newswire (Canada) - 8/23/2017 11:39:00 AM
As Recreational Cannabis Legalization Looms, the Field of Opportunity is Green for Canada’s Leading Growers NetworkNewsWire - 8/23/2017 8:45:00 AM
Canadian Cannabis Leaders Sharpen Focus on Increasing Yield, Plant Quality NetworkNewsWire - 8/22/2017 8:45:00 AM
MJAC 2017 - Speaker Update - Investing In The U.S. Cannabis Market InvestorsHub NewsWire - 8/22/2017 1:27:13 AM
Investors Eye Sweet Spots in Canada’s Booming Cannabis Market NetworkNewsWire - 8/16/2017 8:45:00 AM
Green Rush taking Hold in Canada as US Lawmakers Continue to Spin Tires NetworkNewsWire - 8/15/2017 8:45:00 AM
NetworkNewsWire Member Level  Tuesday, 09/19/17 03:41:57 PM
Re: None
Post # of 356 
Compensated Awareness Post - View Disclaimer
At ABCN, Medicinal Cannabinoid Quality and Safety are Founding Principles

- Producer of consistent, standardized medicinal cannabis
- Menu of cannabis strains with varying CBD:THC ratios
- ABcann’s CBD-Med is one of Canada’s highest-CBD products

In an interview with Cantech Letter (, Aaron Keay, CEO of ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), talked about the factors that triggered the genesis of the company, one of Canada’s trailblazing producers of medicinal cannabis. Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available. Although, in general, not much of a bother to recreational users, to those using cannabis for pain relief or other medical purposes, this was causing a great deal of concern.

Inconsistency in product quality makes the determination of optimal dosage levels impossible to achieve. As a result, “to deliver consistent, standardized medicinal cannabis that the public and patients can consistently rely on” became one of ABcann’s founding principles. That principle continues to guide the company to this day. The Canadian-licensed producer recently announced the release of one of Canada’s highest legal CBD:THC ratio cannabis products. This new product expands the range of therapies now available to patients and so increases the efficacy of current treatment regimens in the promising new field of cannabinoid therapies.

At present, the majority of cannabinoid therapies are directed to alleviate the chronic pain resulting from a variety of maladies. Since delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the cannabinoids occurring at the highest concentrations in cannabis, the therapeutic effects of the plant and its derivatives are most likely derived from these components acting alone or together.

This is a line of research that has been explored successfully by GW Pharmaceuticals. The European company produces Sativex, a treatment for the relief of symptoms in patients with moderate to severe spasticity due to multiple sclerosis (MS), which contains a one-to-one ratio of THC to CBD. While many patients have found relief from pain in high-THC cannabis, a subset of these have reported short-term memory impairment, dysphoria (feeling uneasy for no apparent reason), increased levels of anxiety and even panic attacks. Fortunately, CBD is devoid of such malignant manifestations, exhibiting calming and uplifting properties that appear to mitigate the unwanted effects of THC. As a result, strains of cannabis that are rich in CBD, like those produced by ABcann, are most helpful to those averse or intolerant to THC and to patients who want pain relief without too much of a ‘high’.

A look at the stats released by Health Canada will show where ABcann is on the CBD:THC ratio spectrum. Most cannabis strains (54%) on the Canadian market have a high CBD:THC ratio, with THC over 15% and CBD less than 1%. Many others (29%) have less THC but negligible amounts of CBD, with THC less than 15% and CBD under 1%. Only 14% of strains have both THC and CBD levels that exceed 5%, and just 3% of strains have less than 1% THC and more than 9% CBD, a highly prized category in which the latest ABcann strains can be found.

Late last month, the company announced ( the release of its top-of-the-line CBD-Med, which has a ratio of 27.6:1 (18.5% CBD to 0.67% THC). This adds to ABcann current lineup of high-CBD products, which already include NC:Med, with 18.9% CBD to 1% THC and DC:Med, with 15.4% CBD to 1% THC. ABcann also expects to be able to sell oils from October 2017, a range that will include a 1:1 THC/CBD drop, a high THC dropper and a high CBD dropper.

For more information, visit the company’s website at

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist